Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

agreed

ESS was just a short term remedy (3 years) to getting to revenue recognition - to pay for MANF's runway

problem is - they shot their wade with $34-Mil. of RS funding in Fall, 2014, on ESS, MS-Precise and Georgetown Assays - when none of them were revenue producing whatsoever - what was Leadership thinking???

Eltopra did not have stellar Ph. 2 test results

LymPro and MS Precise are off the books - looking for funding for their developmental runway

and NuroPro, SeraPro and PhenoGuard are all on the back stove

so they either get clean non-dilutive funding to take out Magna. or their IP faces the auction block under Josh

AJMHO